Prolyl-glutaminsaeure | 67644-00-2

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Prolyl-glutaminsaeure
• 英文别名: Prolyl-Glutamate；2-(pyrrolidine-2-carbonylamino)pentanedioic acid
• CAS: 67644-00-2
• 化学式: C₁₀H₁₆N₂O₅
• mdl: MFCD13214170
• 分子量: 244.247
• InChiKey: QLROSWPKSBORFJ-UHFFFAOYSA-N

物化性质

• 溶解度：
  甲醇（微溶）、水（微溶）
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -4.2
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 储存条件：
  -20°C，干燥且密封保存。

制备方法与用途

H-Pro-Glu-OH是一种由致病性分枝杆菌通过VII型分泌系统分泌的蛋白质，它通过ESX-5途径将LipY脂酶靶向至细胞表面。

文献信息

• Morpholino oligonucleotide manufacturing method
  申请人：AJINOMOTO CO., INC.

  公开号：US10472624B2

  公开（公告）日：2019-11-12

  Morpholino oligonucleotides can be produced efficiently in a high yield by a liquid-phase synthesis method, which includes subjecting a reaction mixture of a condensation reaction to an extraction operation and separating the morpholino oligonucleotide as a resultant product to the organic layer side.

  Morpholino寡核苷酸可以通过液相合成方法高效地产生高产量，该方法包括将缩合反应的反应混合物进行萃取操作，并将Morpholino寡核苷酸作为结果产物分离到有机层侧。
• MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD
  申请人：AJINOMOTO CO., INC.

  公开号：EP3208277A1

  公开（公告）日：2017-08-23

  The present invention relates to a liquid-phase synthesis method of morpholino oligonucleotide, which includes subjecting a reaction mixture of a condensation reaction to an extraction operation and separating morpholino oligonucleotide as a resultant product to the organic layer side. According to the present invention, a method capable of producing morpholino oligonucleotide efficiently in a high yield by a liquid-phase synthesis method can be provided.

  本发明涉及一种吗啉寡核苷酸的液相合成方法，该方法包括将缩合反应的反应混合物进行萃取操作，并将吗啉寡核苷酸作为所得产物分离到有机层一侧。根据本发明，可以提供一种通过液相合成法高效、高产地生产吗啉寡核苷酸的方法。
• PLATINUM COMPLEXES AND USES THEREOF
  申请人：L.E.A.F Holdings Group LLC

  公开号：EP3706801A1

  公开（公告）日：2020-09-16
• SYSTEMS AND METHODS FOR MEASURING OBESITY USING METABOLOME ANALYSIS
  申请人：Human Longevity, Inc.

  公开号：US20190310269A1

  公开（公告）日：2019-10-10

  The disclosure relates to systems, software and methods for diagnosis or prognosis of subjects for obesity or a disease related thereto, including, classification and treatment of subjects who have been diagnosed with or deemed at risk of having obesity. The methods are based, in part, on the detection of the levels or activities of a plurality of metabolites or their derivatives, such as levels of amino acids, carbohydrates, lipids, nucleic acids, and/or cofactors, in the subject's biological sample, e.g., blood.
• ENCAPSULATION OF GASTRIC RESIDENCE SYSTEMS
  申请人：Lyndra, Inc.

  公开号：US20200281851A1

  公开（公告）日：2020-09-10

  Compactable gastric residence systems comprising therapeutic agent formulations for sustained gastric release of therapeutic agents are disclosed, as well as methods and systems for encapsulating such gastric residence systems. Hie methods and systems for encapsulating the gastric residence systems can be automated from receiving a bulk of gastric residence systems, orienting, placing, compacting, securing, and encapsulating the gastric residence systems.